A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Secondary to Age‑Related () (AVENUE)

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to (AMD)

  • Eye Disorder
  • Age-Related Macular Degeneration
  • Choroidal neovascularization